ReviewFrontiers in medicine2022
An Updated Review and Meta Analysis of Lipoprotein Glomerulopathy.
Review in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- Early-onset lipoprotein glomerulopathy in a 23-month-old boy with homozygous APOE Kyoto variant.Pediatric nephrology (Berlin, Germany) · 2026Article
- A case of lipoprotein glomerulopathy in which complete remission was achieved by pemafibrate therapy.CEN case reports · 2026Article
- The First Case of Lipoprotein Glomerulopathy in a Patient With Male Infertility.Kidney medicine · 2026Article
- Clinical characteristics and APOE variant spectrum in Chinese patients with lipoprotein glomerulopathy.Chinese medical journal · 2026Article
- Lipids in kidney diseases: from systemic imbalance to intrarenal alterations of cellular lipid metabolism in rare and common kidney diseases.Journal of molecular medicine (Berlin, Germany) · 2026Review
- Deciphering the complexity: a case of kidney failure with co-inheritance of COL4A5 and APOE variants.BMC nephrology · 2026Article
- Identification of a founder haplotype ofClinical kidney journal · 2025Article
- Normolipidemic lipoprotein glomerulopathy with IgA nephropathy - ApoE Kyoto mutation: a case report.Diagnostic pathology · 2025Article
- Impact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features.Journal of atherosclerosis and thrombosis · 2025Review
- First patient diagnosed with lipoprotein glomerulopathy and Alport syndrome.Nephrology (Carlton, Vic.) · 2024Article
- Clinicopathological characteristics and gene mutations in 11 patients with lipoprotein glomerulopathy.Renal failure · 2024Article
- Lipoprotein glomerulopathy: a rare cause of steroid-resistant nephrotic syndrome in a child.CEN case reports · 2024Article
- Variants in tubule epithelial regulatory elements mediate most heritable differences in human kidney function.bioRxiv : the preprint server for biology · 2024Article
- Lipoprotein glomerulopathy with markedly increased arterial stiffness successfully treated with a combination of fenofibrate and losartan: a case report.BMC nephrology · 2024Article
- A case report of youth-onset lipoprotein glomerulopathy with APOE Chicago mutation.BMC nephrology · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
More than 200 cases of lipoprotein glomerulopathy (LPG) have been reported since it was first discovered 30 years ago. Although relatively rare, LPG is clinically an important cause of nephrotic syndrome and end-stage renal disease. Mutations in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.